We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-23.86%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.2B
AUM Growth
-$1.2B
Cap. Flow
+$5.31M
Cap. Flow %
0.17%
Top 10 Hldgs %
52.42%
Holding
74
New
3
Increased
14
Reduced
34
Closed
4

Top Buys

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.1M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$31.7M
3
CNC icon
Centene
CNC
+$23.6M
4
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$18.2M
5
RAPT
RAPT Therapeutics
RAPT
+$17.7M

Top Sells

Rank Stock Value
1
ICUI icon
ICU Medical
ICUI
+$27.6M
2
GMAB icon
Genmab
GMAB
+$26.2M
3
UNH icon
UnitedHealth
UNH
+$24.6M
4
ZGNX
Zogenix, Inc.
ZGNX
+$16.2M
5
ELV icon
Elevance Health
ELV
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Consumer Staples 2.8%
3 Industrials 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$325M
$502M 15.68%
12,957,222
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$211M 6.6%
22,329,386
-386,700
-2% -$3.63M
ARGX icon
3
argenx
ARGX
$52.9B
$163M 5.08%
515,943
-5,700
-1% -$1.66M
LIVN icon
4
LivaNova
LIVN
$4.35B
$161M 5.03%
1,970,511
-86,667
-4% -$6.74M
KRYS icon
5
Krystal Biotech
KRYS
$10B
$121M 3.77%
1,815,698
-5,200
-0.3% -$325K
KYMR icon
6
Kymera Therapeutics
KYMR
$9.14B
$111M 3.45%
2,615,030
+27,300
+1% +$1.15M
ADCT icon
7
ADC Therapeutics
ADCT
$160M
$109M 3.41%
7,432,429
-18,600
-0.2% -$295K
SNCE
8
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$106M 3.31%
990,412
– –
BEAM icon
9
Beam Therapeutics
BEAM
$2.71B
$105M 3.28%
1,836,050
-49,800
-3% -$3.27M
SKIN icon
10
SkinHealth Systems
SKIN
$102M
$89.5M 2.8%
5,304,505
+221,700
+4% +$3.66M
IGMS
11
DELISTED
IGM Biosciences
IGMS
$89.1M 2.78%
3,334,355
– –
CLDX icon
12
Celldex Therapeutics
CLDX
$2.78B
$69.7M 2.18%
2,046,269
-119,317
-6% -$3.81M
ABSI icon
13
Absci
ABSI
$1.38B
$67.7M 2.11%
8,031,094
– –
RGNX icon
14
Regenxbio
RGNX
$557M
$65.6M 2.05%
1,976,923
+79,700
+4% +$2.21M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$63.6M 1.98%
441,274
+69,435
+19% +$9.39M
REPL icon
16
Replimune Group
REPL
$882M
$62.7M 1.96%
3,691,312
-175,200
-5% -$3.31M
ATRA icon
17
Atara Biotherapeutics
ATRA
$74.7M
$58M 1.81%
249,836
-7,675
-3% -$2.44M
CNC icon
18
Centene
CNC
$32.5B
$54.6M 1.71%
648,837
+287,698
+80% +$23.6M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$43.9M 1.37%
9,217,945
+959,600
+12% +$5.31M
STOK icon
20
Stoke Therapeutics
STOK
$1.72B
$42.6M 1.33%
2,024,368
-222,300
-10% -$4.45M
NRIX icon
21
Nurix Therapeutics
NRIX
$2.36B
$42.3M 1.32%
3,018,784
+60,500
+2% +$1.07M
AUGX
22
DELISTED
Augmedix, Inc. Common Stock
AUGX
$42.3M 1.32%
14,380,327
– –
VERV
23
DELISTED
Verve Therapeutics
VERV
$41.9M 1.31%
1,835,328
+126,792
+7% +$3.62M
ELV icon
24
Elevance Health
ELV
$82.9B
$40.9M 1.28%
83,162
-27,127
-25% -$12.4M
RPTX
25
DELISTED
Repare Therapeutics
RPTX
$38.9M 1.21%
2,732,996
-56,500
-2% -$838K
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2022 Portfolio in Review

As of Q1 2022, Redmile Group held 74 positions worth $3.2B, down 27% from $4.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Redmile Group's Q1 2022 filing shows 3 new, 14 increased, 34 reduced and 4 closed positions. Its largest new stake was 1Life Healthcare: 3,404,835 shares worth $37.7M. The largest sale was ICU Medical, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Redmile Group's largest Q1 2022 buy was 1Life Healthcare: 3,404,835 shares worth $37.7M.
  • Redmile Group added most to Centene in Q1 2022, an estimated $23.6M increase.
  • Redmile Group's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $27.6M.
  • Redmile Group fully exited Genmab in Q1 2022, selling an estimated $26.2M.
  • Redmile Group's ten largest holdings make up 52% of its $3.2B portfolio in Q1 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q1 2022.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $3.2B.

Based on Redmile Group's 13F filing for Q1 2022, filed 16 May 2022.